Gerard Rosse
ACS Med. Chem. Lett. 2022, 13, 1, 11–12
https://doi.org/10.1021/acsmedchemlett.1c00643
The compounds of this patent application represent a potential treatment for cancer characterized by KRAS, HRAS, and NRAS GC12 mutation. The compounds have the ability to inhibit the G12C mutant of KRAS, HRAS, and NRAS via the formation of an irreversible bond to cysteine 12. The irreversible binding locks KRAS in an inactivate state and disrupts downstream signaling.
